169 related articles for article (PubMed ID: 27089226)
1. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
[TBL] [Abstract][Full Text] [Related]
2. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
3. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
5. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
Richey SL; Culp SH; Jonasch E; Corn PG; Pagliaro LC; Tamboli P; Patel KK; Matin SF; Wood CG; Tannir NM
Ann Oncol; 2011 May; 22(5):1048-1053. PubMed ID: 21115604
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
[TBL] [Abstract][Full Text] [Related]
8. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S;
Eur Urol; 2013 Apr; 63(4):745-52. PubMed ID: 23063454
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
10. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
11. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
[TBL] [Abstract][Full Text] [Related]
12. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
Halabi S; Rini B; Escudier B; Stadler WM; Small EJ
Cancer; 2014 Jan; 120(1):52-60. PubMed ID: 24347384
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Rebibo JD; Pfister C; Giwerc A; Defortescu G; Gouerant S; Di Fiore F; Nouhaud FX
Prog Urol; 2016 Jan; 26(1):16-23. PubMed ID: 26455779
[TBL] [Abstract][Full Text] [Related]
17. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
[TBL] [Abstract][Full Text] [Related]
18. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis.
Zanwar S; Joshi A; Noronha V; Patil VM; Sable N; Popat P; Menon S; Kothari R; Bhargava P; Kapoor A; Prabhash K
Indian J Cancer; 2016; 53(4):579-582. PubMed ID: 28485356
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
[TBL] [Abstract][Full Text] [Related]
20. Statins and survival outcomes in patients with metastatic renal cell carcinoma.
McKay RR; Lin X; Albiges L; Fay AP; Kaymakcalan MD; Mickey SS; Ghoroghchian PP; Bhatt RS; Kaffenberger SD; Simantov R; Choueiri TK; Heng DY
Eur J Cancer; 2016 Jan; 52():155-62. PubMed ID: 26687834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]